Astellas Pharma Gmbh

Saturn Licensing LLC

Hitachi, Ltd.

Soichiro Nakamura

Yuuki Takaishi

Yutaka Takahashi

Ken Yano

Hirotaka Tako

Daisuke Murayama

Kazuhiro Sako

Keiichi Takahashi

Shin Yamamoto

Hiroyasu Sato

Takashi Nishizato

Emiko Murayama

Masao Kondo

Kazuya Tateishi

Takanobu Wada

Shunsuke Kajiura

Ichio Shimizu

Akio Hoshi

Sumio Okada

Hiroki Aono

This disclosure relates to a connection device that can provide a new function for an electronic device. A film antenna receives a wireless signal transmitted by radio, a relay unit relays the received wireless signal to a television receiver, an LED indicator emits light based on a control signal transmitted from the television receiver, a storage case stores the film antenna, the relay unit and a light emitting unit, and a connection member connects the storage case to the television receiver. In addition, in a state of being connected to the television receiver, in a normal direction to a housing surface having a display unit on a housing of the television receiver, the storage case has a protruding section which further protrudes from the housing surface and stores the film antenna in the protruding section. For example, this disclosure can be applied to a receiving device having a receiving unit which receives the wireless signal.

Television receiver coupled to a connection device

A pharmaceutical composition for modified release comprising (R)-2-(2-aminothiazol-4-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide or a pharmaceutically acceptable salt thereof, and a carrier for a sustained release pharmaceutical composition, wherein a maximum blood drug concentration (Cmax) when administered in fasted state is 400 ng/ml or less, is disclosed.

Pharmaceutical composition for modified release

A pharmaceutical composition for modified release, comprising (1) (R)-2-(2-aminothiazol-4-yl)-4'-[2-[(2-hydroxy-2-phenylethyl) amino]ethyl] acetic acid anilide, or a pharmaceutically acceptable salt thereof, (2) at least one additive which ensures penetration of water into the pharmaceutical composition and which has a solubility such that the volume of water required for dissolving 1 g of the additive is 10 mL or less, and (3) a hydrogel-forming polymer having an average molecular weight of approximately 100,000 or more, or a viscosity of 12 mPa·s or more at a 5% aqueous solution at 25 C is disclosed.

A pharmaceutical composition for modified release comprising (R)-2-(2-aminothiazol-4-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide or a pharmaceutically acceptable salt thereof, and a carrier for a sustained release pharmaceutical composition, wherein a maximum blood drug concentration (Cmax) when administered in a fasted state is 400 ng/mL or less, is disclosed.

Connection device

Charging station for robot

Autonomous mobile robot

A pharmaceutical composition for modified release, comprising (1) (R)-2-(2-aminothiazol-4-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide, or a pharmaceutically acceptable salt thereof, (2) at least one additive which ensures penetration of water into the pharmaceutical composition and which has a solubility such that the volume of water required for dissolving 1 g of the additive is 10 mL or less, and (3) a hydrogel-forming polymer having an average molecular weight of approximately 100,000 or more, or a viscosity of 12 mPa&#xb7;s or more at a 5% aqueous solution at 25&#xb0; C. is disclosed.

The present disclosure relates to a light emitting device that can improve design of emitted light. A communication substrate is provided with an LED indicator which emits light. A light guiding plate has a concave surface portion which is a concave surface to cover the LED indicator, and receives the light from the LED indicator using the concave surface portion. A storage case stores the communication substrate and the light guiding plate in a state where a part of the light guiding plate is exposed. The light guiding plate allows the light from the LED indicator to penetrate to a part of the light guiding plate exposed from the storage case by diffusing the light received using the concave surface portion. For example, the present disclosure is applicable to the light emitting device that emits light using an LED or the like.

Light emitting device

A pharmaceutical composition for modified release comprising (R)-2-(2-aminothiazol-4-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide or a pharmaceutically acceptable salt thereof, and a carrier for a sustained release pharmaceutical composition, wherein a dissolution rate of the drug from the composition is less than 85% after 30 minutes from the beginning of a dissolution test, is disclosed.

The present invention provides a surface mount Gull-Wing type resin-encapsulating package for encapsulating a semiconductor chip, wherein the cut face (outer tip end) of each outer lead is formed to have a smaller cross-sectional area than that of each outer lead, for improving the extension of solder to the cut face of that lead. Such relatively smaller cross-sectional area of the outer tip end of each outer lead reduces the exposed area of the lead material when disconnecting the leads from the frame in separating the device from the frame.

Growing community of inventors

Tokyo, Japan

Soichiro Nakamura